List of candidates proposed for the election of the Executive Committee
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
List of candidates proposed
for the election of the Executive Committee
of the 17th legislative period
Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.
Gemeinnütziger wissenschaftlicher Verein
International Association for Pharmaceutical Technology
APV
Kurfürstenstraße 59
55118 Mainz/Germany
+49 6131 9769-0
+49 6131 9769-69
apv@apv-mainz.de
www.apv-mainz.de
Executive Committee of the APV (2018-2022) - preliminary list of candidates
List of candidates proposed for the election of
the Executive Committee
Persons
Prof. Dr. Johannes Bartholomäus Prof. Dr. Sandra Klein
TU Braunschweig and Institut für Pharmazie
Pharmakreativ Pharmaceutical Development Biopharmazie und Pharmazeutische Technologie
Consulting Ernst-Moritz-Arndt-Universität Greifswald
Burghöhenweg 5 Felix-Hausdorff-Strasse 3
52080 Aachen 17489 Greifswald
Germany Germany
Dr. Kathrin Bartscher Dr. Hans Lindner
NextPharma Bayer AG
Im Wirrigen 25 Müllerstrasse 178
45731 Waltrop 13353 Berlin
Germany Germany
Dr. Karoline Bechtold-Peters Dr. Martin Lück
Novartis Pharma AG Grünenthal GmbH
4002 Basel Zieglerstraße 6
Werk Klybeck 52078 Aachen
Switzerland Germany
Prof. Dr. Jörg Breitkreutz Dr. Alexandra Steckel
Institute of Pharmaceutics and Alfred E. Tiefenbacher GmbH & Co. KG
Biopharmaceutics Van-der-Smissen-Strasse 1
Heinrich-Heine-University Düsseldorf 22767 Hamburg
Universitätstr. 1 Germany
40225 Düsseldorf
Germany
Dipl.Ing.(TU) Roland Szymoniak
Sanofi-Aventis Deutschland GmbH
Prof. Dr. Heribert Häusler Industriepark Höchst
Vorm. Boehringer Ingelheim 65926 Frankfurt/Main
Richard Sorge Straße 73a Germany
10249 Berlin
Germany
Prof. Dr. Stefan W. Hockertz
tpi consult GmbH – toxicology-pharmacology-
immunology
Ölbergweg 58
79283 Bollschweil, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Prof. Dr. Johannes Dr. Kathrin
Bartholomäus Bartscher
born 1959 born 1978
in Lohne i.O. in Brilon
Germany Germany
Prof. Dr. Johannes (Hans) Bartholomäus studied Pharmacy Dr. Kathrin Bartscher studied Pharmacy at the Westphalian
(1979-1983) at the TU Braunschweig, Germany, followed Wilhelms-University of Muenster (Germany). After finishing
by the practical year in the Adler Apotheke, Borken, and her doctoral thesis at the Institute for Pharmaceutical
Kettelhack Riker Pharma, Borken (1983-1984). He finished Technology and Biopharmaceutics in Muenster under
his thesis at the Institute of Pharmaceutical Technology supervision of Prof. Dr. R. Gröning in 2006 she joined
of TU Braunschweig under the supervision of Prof. Dr. NextPharma as formulation scientist. In 2013 she was
C. Führer (1988). Hans started his industrial career at appointed as Head of Drug Product Development at
Grünenthal GmbH as Head of the Solid Oral Dosage Forms the NextPharma site in Waltrop. 2016 she took over the
Lab and from 1992 to 2008 he was heading Pharmaceutical global responsibility for the development activities at all
Development of Grünenthal. In 2009 Hans started his own NextPharma sites and joined the NextPharma board in July
Pharmaceutical Development Consultancy. Besides, he is 2017 as Chief Scientific Officer.
an invited lecturer (since 2001) for Industrial Pharmacy and
Honorary Professor (2009) at TU Braunschweig. Currently She was initiator of the first APV local group in Dortmund.
he is teaching pharmaceutical quality system for Master of Since 2014 she is member of the APV board and treasurer
Pharmaengineering. His special professional interests are of APV.
Drug Delivery, Life Cycle Management, IP Management,
Quality Systems, Drug Stability, Clinical Supplies and Objectives:
Pharmaceutical Development Strategies including Quality • Increasing the APV membership value by
by Design. ºº Increasing the opportunities for active contribution
to APV activities especially for young colleagues
Hans became member of APV during his Ph.D. studies ºº Growing APV as platform for scientific exchange
mid of the 1980ies. He was a co-founding member of • Improving the visibility and perception of APV in the
APV’s Drug Delivery Focus Group in 2003 and became market
chairman of this group in 2014. He was member of the • Making the difference with our seminar & conference
program committees of the 1st European Conference on program by strengthening the international and
Pharmaceutics in Reims (2015) and the 11th World Meeting interdisciplinary focus
on Pharmaceutics, Biopharmaceutics and Pharmaceutical • Re-activating, strengthening and growing the active
Technology in Granada (2018). participation of APV members from pharmaceutical
industry
Objectives: • Assuring continuity of a stable financial situation as
• Strengthen internationalization of APV and making basis for the realization of all our future objectives and
APV visible as the European platform for Pharmaceutics, visions
Biopharmaceutics and Pharmaceutical Technologists in
Academia, Regulatory Bodies and Industry
• Grow networking opportunities for members and
participants and increase value of APV membership
• Improve quality of APV processes and standards
Prof. Dr. Johannes Bartholomäus
TU Braunschweig and Pharmakreativ Pharmaceutical Dr. Kathrin Bartscher
Development Consulting NextPharma
Burghöhenweg 5 Im Wirrigen 25
52080 Aachen, Germany 45731 Waltrop, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Dr. Karoline Prof. Dr. Jörg
Bechtold-Peters Breitkreutz
born 1964 born 1966
in Munich in Marl
Germany Germany
Dr. Karoline Bechtold-Peters is pharmacist and received Prof. Dr. Jörg Breitkreutz studied Pharmacy (1987-
her doctorate from the Ludwigs-Maximilians-University of 1991) at the Westphalian Wilhelms-University, Münster,
Munich in Pharmaceutical Technology in 1994 for a thesis Germany. He finished his thesis in 1996 at the Institute
in the field of enteric-coated pancreatin pellets. In 1994, for Pharmaceutical Technology and Biopharmaceutics in
Karoline started at Boehringer Ingelheim in Ingelheim as Münster, under supervision of Prof. Dr. R. Gröning. From
Head of Laboratory in Solid Dosage Forms, focusing on 1996 to 1997 he joined Thiemann Arzneimittel GmbH in
powder inhalation therapeutics. In this context, Karoline was Waltrop, Germany, as the head of Product Coordination. In
instrumental in the development of the blockbuster Spiriva. 1997 he went back to the university in Münster finishing his
In 2000, she moved to the Business Unit Biopharmaceuticals habilitation thesis on paediatric drug formulations in 2004.
of Boehringer Ingelheim and thus to Biberach to build-up Since 2004 he holds a professorship for pharmaceutical
Formulation Development of Therapeutic Proteins. In 2003 technology at the Heinrich-Heine-University in Düsseldorf,
she was appointed 2003 Head of Global Clinical Supplies, Germany. In 2009 he became an APV board member and
Aseptic Process Development and Process Transfer. After in 2010 he was elected for president.
several years in this position, Karoline moved to Basel,
Switzerland, in 2011, to join Hoffmann La-Roche and was His research focuses on patient-centric drug development
assigned Head of Drug Product Clinical Supply Center Basel (in particular for children), orphan drugs, process analytical
within Global Biologics Europe and was responsible for the technologies and Green Pharmacy. Jörg Breitkreutz is
production of biopharmaceutical clinical supplies both for
member of various international societies and networks,
Roche and Genentech. It became her core task to ramp
Fellow and member of the the Association of American
up the brand new clinical lines for sterile vials and syringes
Pharmaceutical Scientists (AAPS).
covering initial inspections and initial batch production from
2011 to 2013. The expansion of the production to Antibody-
Objectives:
Drug-Conjugates followed. In 2016, Karoline joined Novartis
• Making APV the home society of all scientists engaged
Pharma AG in Basel to focus on more strategic issues of
Biopharmaceuticals as Senior Strategy and Technology Leader in pharmaceutical technology and industrial pharmacy
Pharmaceutics within Biologics Technical Development & • Binding APV members a whole life long
Manufacturing. Karoline is member of APV since 1994. • Linking academia and pharmaceutical industry
Besides this she is active in several international organisations • Involvement in public funding programs
such as AAPS, PDA and EBE/EFPIA and is frequently invited to • Strengthening the European leadership of APV
contribute to conferences and papers or books.
Objectives:
• Ensure that APV is on top of the relevant industry topics
• Strengthen Biopharmaceuticals within APV
• Connect APV increasingly to international work streams,
further drive the international orientation of APV and
strengthen international collaborations
• Increase the value of APV membership by addressing
burning topics
Prof. Dr. Jörg Breitkreutz
Dr. Karoline Bechtold-Peters Institute of Pharmaceutics and Biopharmaceutics
Novartis Pharma AG Heinrich-Heine-University Düsseldorf
4002 Basel Universitätstr. 1
Werk Klybeck, Switzerland 40225 Düsseldorf, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Prof. Dr. Heribert Prof. Dr. Stefan W.
Häusler Hockertz
born 1948 born 1960
in Saarbrücken in Hannover
Germany Germany
Prof. Dr. Heribert Häusler studied chemistry at Saarbrücken Professor Dr. rer. nat. Stefan W. Hockertz is an immunologist
University and obtained his promotion at the Institute and toxicologist, now as CEO of the tpi consult GmbH, one
for Analytical Chemistry and Radiochemistry. From1979 of the European leading toxicological and pharmacological
to 2013 he worked for Boehringer Ingelheim. There he technology consulting companies. Previously, he served
was Head of the Department Pharmaceutical Production as Director and Professor of the Institute of Experimental
Non Solids until 2002 and was then responsible as Vice and Clinical Toxicology at the University Medical School
President for Department Quality Operations at both sites Eppendorf in Hamburg from 2003 to end of 2004.
Biberach and Ingelheim until 2012. Up to his retirement in Prior to joining the University, he served as Director of
2013 he acted as a VP in the Corporate Function Quality the Fraunhofer Institute of Toxicology and Environmental
Systems Excellence. As a honorary professor he got a Medicine Hamburg from 1995 to 2002 and before as
lectureship for Quality Assurance and Quality Strategy at an investigator at the Fraunhofer Institute of Toxicology
Mainz University. Since 2017 he has been teaching quality and Aerosol Research in Hannover from 1986 to 2001.
management at Beuth University of Applied Sciences. He received his first academic appointment to Hannover
University in 1985.
Prof. Dr. Häusler has also made his mark as an author of Prof. Hockertz is appointed as “Eurotox Registered
scientific publications and EuAB comments. Prof. Dr. Toxicologist” and he has the admission as „Herstellungs-
Häusler is a member of the APV since 1998. Since 2004 he and Kontrolleiter“ according to §15.1 and §15.3 of the
is Vice President of the APV and responsible for German Drug Law since 1996. Hockertz holds a doctorate
the focus groups Analytics/Quality Assurance and in biology from the University Hannover and he is a
Information Technology. University Professor for Molecular Immunotoxicology of
the University Hamburg Medical School.
Objectives: Prof. Hockertz has wide experience as a former board
• To increase cooperations between APV and industrial member of a german pharma association. As member
associations of the APV he is working in the Task Force „Individual
• To establish cooperations between pharmaceutical Medicines“ and he is a guest at the Focus Groups „Drug
engineers and industrial pharmacists Regulatory Affairs“ and „Drug Delivery“.
• To continue working in the Executive Committee and
to contribute to the pofessionalization of APV Objectives:
• To further develop the focus groups Analytic and • Strengthen the area of preclinical safety and toxicology
Quality assurance as well as Information Technology in the APV.
• Conditioning the APV for modern and innovative
topics like precise medicine and individual medicines.
• Improving toxicological knowledge of the APV
members in drug development, manufacturing,
pharmacovigilance and pharmaceutical technology.
• Increase the number of members by increasing the
APV membership value.
Prof. Dr. Heribert Häusler Prof. Dr. Stefan W. Hockertz
Vorm. Boehringer Ingelheim tpi consult GmbH – toxicology-pharmacology-immunology
Richard Sorge Straße 73a Ölbergweg 58
10249 Berlin, Germany 79283 Bollschweil, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Prof. Dr. Sandra Dr. Hans Lindner
Klein born 1963
born 1970 in Kiel
in Büdingen Germany
Germany
Prof. Dr. Sandra Klein studied Pharmacy at the University of Hans Lindner is a pharmacist and holds a doctorate degree
Frankfurt, Germany and graduated in 2000. At the same in pharmaceutical technology from Christian-Albrechts-
university she started her graduate studies at the Institute University, Kiel.
of Pharmaceutical Technology under the supervision of
Jennifer Dressman. She got her PhD in 2005 and was then He started his industrial career at Arzneimittelwerk Dresden
a postdoctoral fellow at Eastman Chemical Company in in 1994, where he led a scale up team in formulation
Kingsport/TN, USA. From 2006 till 2010 Sandra Klein was a development. In 1996, he joined Ferring Pharmaceuticals
senior research associate at the Institute of Pharmaceutical first in Germany, moving later to Denmark. At Ferring, he
Technology at the University of Frankfurt. Since 2010 she served in various positions with increasing responsibilities
is Professor of Pharmaceutical Technology at the University in formulation and pharmaceutical development, at the
of Greifswald, Germany. end overseeing CMC development.
Her current research is focusing on the development of
bio-predictive dissolution methods for special patient He joined Schwarz Pharma in 2004, leading pharmaceutical
groups, particularly the pediatric and geriatric population development. After integration into UCB in 2007, he
and of patient-centric formulations. Other research managed the late stage product development function.
interests include the design of predictive and accelerated In 2008, he joined Bayer, heading pharmaceutical
test methods for vaginal delivery systems and depot development. In 2012 took responsibility for a newly
parenterals and the enhancement of the bioavailability of formed unit overseeing all external activities in
poorly soluble drug compunds with different polymer- and pharmaceutical development. Since 2014, he is heading
cyclodextrin-based approaches. alliance management for research. He leads a global team,
Sandra Klein is an APV member since 2000 and member developing and running innovative collaboration models
of the American Association of Pharmaceutical Scientists with numerous research partners.
(AAPS), the Controlled Release Society (CRS) and a core
member of the European Paediatric Formulation Initiative During his career, Hans has been working with a wide
(EuPFI) amongst others. variety of dosage forms, technologies and delivery systems.
He has experience in managing functions, technology
Objectives: and knowledge transfers, as well as internal and external
• Linking APV to the global pharmaceutical network, interfaces in different organizations.
i.e. strengthening the collaboration of APV with other
international societies, universities and industry Objectives:
• Further increasing the visibility of APV • Continue internationalization of APV
• Improving collaboration of academia and industry • Support and promote collaboration and network
• Binding young pharmacists to APV giving them the within APV
chance to actively participating in activities of the APV • Further Develop and promote APV as valuable
network organization for its members
Prof. Dr. Sandra Klein
Institut für Pharmazie
Biopharmazie und Pharmazeutische Technologie Dr. Hans Lindner
Ernst-Moritz-Arndt-Universität Greifswald Bayer AG
Felix-Hausdorff-Strasse 3 Müllerstrasse 178
17489 Greifswald, Germany 13353 Berlin, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Dr. Martin Lück Dr. Alexandra
born 1968 Steckel
in Rendsburg born 1982
Germany in St. Petersburg
Russia
Dr. Martin Lück is Senior Vice President and Head of Drug Dr. Alexandra Steckel studied Pharmacy in St. Petersburg,
Development at Grünenthal GmbH, Aachen (Germany). In Russia. She extended the study at Christian Albrecht
his current role, he oversees all functions involved in the University of Kiel, Germany, and was awarded the MSc
execution of Grünenthal´s Drug Development projects, i.e. degree of the faculty in 2006. She finished her PhD thesis
Toxicology, Pharmacokinetics & Bioanalytics, CMC, Clinical in Pharmaceutical Technology in 2009 at the Institute for
Operations, Clinical Pharmacology, Biostatistics and pharmaceutical Technology and Biotechnology of the
Pharmacometrics. He joined Grünenthal in 2010 as Head Christian Albrecht University of Kiel under supervision of
of Pharmaceutical Development and was appointed Head Prof. Dr. Dr. B. W. Müller.
of CMC in 2014 and Head of Drug Development in 2017.
In 2010 she started her industrial career at Losan
From 1998 to 2010 Dr. Lück held various leadership Pharma GmbH, Germany, as Technology and Business
positions in Pharmaceutical Development and Technical Development Manager where she was responsible for
Operations at Ferring Pharmaceuticals in Germany, new customer acquisitions for contract development and
Denmark and Switzerland. manufacturing services as well as for licensing business for
Losan’s generic portfolio. In 2012 Dr. Alexandra Steckel
Dr. Lück studied Pharmacy at the Christian Albrecht joined Evonik Industies AG, Germany, as Sales Manager
University Kiel. He finished his PhD thesis in Pharmaceutical for Pharmaceutical Excipients (Eudragit® and Resomer®)
Technology at the Free University of Berlin under supervision and Contract Development Services for solid oral and
of Prof. Dr. Rainer H. Müller. He received the APV award for parenteral depot products. In 2015 Dr. Alexandra Steckel
the most outstanding doctoral thesis in the pharmaceutical joined Alfred E. Tiefenbacher (AET), Germany, as Business
sciences in the year 1997. Development Manager where she is active upon now.
Dr. Steckel is responsible for identification and external
Objectives: development of new products for the generic portfolio of
• Strengthen interactions between APV and AET.
Pharmaceutical Industry
• Increase visibility of APV in Pharmaceutical Industry Objectives:
to attract new members and keep members actively • To increase the recognition and visibility of APV
involved as a leading professional and scientific non-profit
• Contribute to APV´s seminar and conference programs organization by developing of a new branding
and communication strategy for APV with external
professionals
• To support the expansion and internalization of APV
Dr. Martin Lück Dr. Alexandra Steckel
Grünenthal GmbH Alfred E. Tiefenbacher (GmbH & Co. KG)
Zieglerstraße 6 Van-der-Smissen-Strasse 1
52078 Aachen, Germany 22767 Hamburg, Germany
Executive Committee of the APV (2018-2022) - list of candidates
Dipl. Ing. Roland
Szymoniak
born 1954
in Mannheim
Germany
Dipl.Ing.(TU) Roland Szymoniak studied Process Engineering
at the Karlsruhe/Germany University.
He started his professional career in 1981 at Hoechst
AG and worked for the successor companies Hoechst
Marion Roussel GmbH and Aventis Pharma and Sanofi-
Aventis first as a plant and process engineer in the active
pharmaceutical ingredient production (API) and later as
technical and engineering support for all API productions
worldwide.
After two years of services as an assistant to the
Management Board of Hoechst´s Pharmaceutical Division
and subsequent years of support for both API and
manufacturing sites worldwide, he took over responsibility
in 1996 as Head of Engineering and Technical Business
support at the site Frankfurt Injectables, the largest
manufacturing site of Sanofi worldwide.
Since January 2010 he assumed worldwide responsibility
for his current job as Head of Industrial Engineering &
Transfers, both supporting sterile manufacturing sites of
Sanofi with global responsibility and being also responsible
for all transfer activities of international production
transfers into Emerging Markets.
From 2010 to 2015 Roland Szymoniak acted as head of the
APV focus group „Pharmaceutical Process Engineering“,
which he joined in 1992 and where he still is an active
member.
Objectives:
• Strengthen the industrial/technical aspects in the
pharmaceutical APV environment, also introducing
inputs from ISPE, the International Society for
Pharmaceutical Engineering
• Support internationalisation of APV and disclosure
of benefits of APV seminar participation to Emerging
Markets
• Increase visibility of APV in electronic media and reveal
benefits for APV members and “not-yet-members”
Dipl.Ing.(TU) Roland Szymoniak
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst
65926 Frankfurt/Main, Germany
Executive Committee of the APV (2018-2022) - list of candidates
You can also read
